Genentech Plans Herceptin Filing In Adjuvant Setting; Survival Benefit Shown

Genentech is preparing to submit a supplemental BLA for Herceptin for the adjuvant treatment of early-stage HER-2 positive breast cancer based on positive interim results from Phase III studies